Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses the latest ‘new kids on the block’ that target PCSK9.

Read the report »

The PCSK9 Forum Editors highlight the latest news from these landmark studies for PCSK9 inhibition.

From ODYSSEY OUTCOMES

• Impact of alirocumab on MI type – and on all-cause death

From FOURIER

• Evolocumab prevented more than double the number of total events compared with first events
• Clinical benefit with evolocumab in chronic kidney disease